ArticleNature2023
CD4
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 210 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
210citing papers in PubMed, 3 pooled it
44.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
210 citing papers in PubMed, 3 syntheses or guidelines pooled it, 272 citations in OpenAlex.
- CD4Sensors (Basel, Switzerland) · 2026Pooled it
- A meta-analysis of experimentally validated neo-epitopes: patterns, biases, and opportunities.Cancer immunology, immunotherapy : CII · 2025Pooled it
- Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Pooled it
- UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity.Cell reports. Medicine · 2025Trial
- Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.Molecular cancer · 2024Trial
- Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial.Nature communications · 2024Trial
- Pleiotropic effects of BET inhibition broadly boost tumor immunogenicity to CD8Oncoimmunology · 2026Article
- Microbiota-derived self-adjuvanting exopolysaccharide-based codelivery system for potent cancer immunotherapy.Materials today. Bio · 2026Article
- Why CD4+ T cells matter in adoptive cell therapy for solid cancers.Immuno-oncology technology · 2026Review
- Interferon regulatory factors orchestrate CD8International journal of molecular medicine · 2026Review
- Assessment of Tfh Cells and Related Molecules in CML-CP Patients With Different Molecular Responses.International journal of laboratory hematology · 2026Article
- Targeting BCL9/BCL9L enhances CD4Acta pharmacologica Sinica · 2026Article
- Spatial T lymphocyte infiltration into the primary melanoma tumor associates with survival.Melanoma research · 2026Article
- Intratumoral T cell activation kills tumors regardless of T cell specificity.Nature immunology · 2026Article
- TIGITCancers · 2026Article
- Generation of effector CD4Stem cell reports · 2026Article
- Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.Science advances · 2026Article
- Pathomics-based machine learning models for predicting METTL5 expression and prognosis in lung adenocarcinoma.Journal of thoracic disease · 2026Article
- 25 Years of Cancer Immunoediting: Dendritic Cells and Macrophages Filled the Missing Gap.Cancers · 2026Review
- MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9⁺ monocyte-macrophage programming and durable antitumor immunity in triple negative breast cancer.Cancer immunology research · 2026Article
150 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 8 institutions in 3 countries.
Bastian Kruse *Laboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany.ORCID 0000-0002-9321-0351
Anthony C Buzzai *Laboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany.ORCID 0000-0001-8295-2950
Naveen Shridhar *Laboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany.
Andreas D Braun *Laboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany.ORCID 0000-0002-6954-0633
Susan GellertLaboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany.ORCID 0000-0001-6340-4406
Kristin KnauthLaboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany.ORCID 0000-0003-3548-4044
Joanna PozniakLaboratory for Molecular Cancer Biology, Center for Cancer Biology, VIB, Leuven, Belgium.
Johannes PetersLaboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany.
Paulina DittmannLaboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany.
Miriam MengoniLaboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany.
Tetje Cornelia van der SluisLaboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany.ORCID 0000-0003-1804-1647
Simon HöhnLaboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany.
Asier AntoranzTranslational Cell and Tissue Research, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Anna KroneInstitute of Molecular and Clinical Immunology, Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany.
Yan FuInstitute of Molecular and Clinical Immunology, Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany.
Di YuDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-8636-0351
Magnus EssandDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-9725-0422
Robert GeffersHelmholtz Centre for Infection Research, Brunswick, Germany.ORCID 0000-0003-4409-016X
Dimitrios MougiakakosDepartment of Hematology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany.ORCID 0000-0002-2817-6660
Sascha KahlfußInstitute of Molecular and Clinical Immunology, Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany.
Hamid KashkarInstitute for Molecular Immunology, Centre for Molecular Medicine Cologne and Cologne Excellence Cluster on Cellular Stress Responses in Ageing-Associated Diseases, University of Cologne, Cologne, Germany.ORCID 0000-0003-2796-1429
Evelyn GaffalLaboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany.
Francesca M BosisioDepartment of Pathology, UZ Leuven, Leuven, Belgium.ORCID 0000-0002-8874-2003
Oliver BechterDepartment of General Medical Oncology, UZ Leuven, Leuven, Belgium.
Florian RambowDepartment of Applied Computational Cancer Research, Institute for AI in Medicine (IKIM), University Hospital Essen, Essen, Germany.
Jean-Christophe MarineLaboratory for Molecular Cancer Biology, Center for Cancer Biology, VIB, Leuven, Belgium.
Wolfgang KastenmüllerInstitute for Systems Immunology, Wuerzburg, Germany.ORCID 0000-0002-3835-1485
Andreas J MüllerInstitute of Molecular and Clinical Immunology, Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany. andreas.mueller@med.ovgu.de.ORCID 0000-0002-0281-6383
Thomas TütingLaboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany. thomas.tueting@med.ovgu.de.ORCID 0000-0001-7146-0934
Otto-von-Guericke-Universität Magdeburg · DEUniversitair Ziekenhuis Leuven · BEUppsala University · SEVIB-KU Leuven Center for Cancer Biology · BEHelmholtz Centre for Infection Research · DEKU Leuven · BEUniversity of Cologne · DEUniversity of Duisburg-Essen · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most clinically applied cancer immunotherapies rely on the ability of CD8
Indexed as
CD4-Positive T-LymphocytesCell DeathImmunotherapyInflammationNeoplasmsTumor MicroenvironmentAntigen-Presenting CellsCD11c AntigenCD8-Positive T-LymphocytesHistocompatibility Antigens Class IIHumansImmunity, InnateInterferonsKiller Cells, NaturalMajor Histocompatibility ComplexMyeloid CellsCD11c AntigenHistocompatibility Antigens Class IIInterferonsNitric Oxide Synthase Type IINOS2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.